| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
37,860,000 |
| Market
Cap: |
940.82(M) |
| Last
Volume: |
386,397 |
Avg
Vol: |
218,081 |
| 52
Week Range: |
$12.33 - $23.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Specialized Health Services |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P SMALLCAP 600 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Artivion is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Co. has the following product families: aortic stents and stent grafts, surgical sealants, On-X® mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stents and stent grafts include JOTEC® stent grafts and surgical products, the Ascyrus Medical Dissection Stent hybrid prosthesis, and the NEXUS® endovascular stent graft system. Surgical sealants include BioGlue® Surgical Adhesive products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,229 |
296,929 |
313,427 |
517,850 |
| Total Sell Value |
$52,561 |
$5,745,284 |
$6,055,258 |
$8,935,238 |
| Total People Sold |
1 |
9 |
9 |
11 |
| Total Sell Transactions |
2 |
65 |
67 |
96 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ronald C Elkins |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
102,849 |
|
- |
|
| Morgan Harvey |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
50,299 |
|
- |
|
| Ronald D Mccall |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
158,511 |
|
- |
|
| Bevevino Daniel J |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
99,349 |
|
- |
|
| Salveson Jon W |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
79,349 |
|
- |
|
| Bullock James W |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
8,266 |
|
- |
|
| Ackerman Thomas F |
Director |
– • – |
2017-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
5,263 |
99,349 |
|
- |
|
| Benson James |
Director |
– • – |
2017-04-03 |
4 |
D |
$16.60 |
$33,200 |
D/D |
(2,000) |
58,086 |
|
- |
|
| Lee David Ashley |
Executive VP, COO & CFO |
• – – |
2017-02-26 |
4 |
D |
$17.25 |
$107,882 |
D/D |
(6,254) |
291,149 |
|
- |
|
| Capps Scott B |
VP, Clinical Research |
• – – |
2017-02-26 |
4 |
D |
$17.25 |
$64,722 |
D/D |
(3,752) |
113,642 |
|
- |
|
| Horton Amy |
VP, Chief Accounting Officer |
• – – |
2017-02-26 |
4 |
A |
$17.25 |
$4,796 |
D/D |
278 |
93,615 |
|
- |
|
| Horton Amy |
VP, Chief Accounting Officer |
• – – |
2017-02-26 |
4 |
D |
$17.25 |
$38,364 |
D/D |
(2,224) |
93,893 |
|
- |
|
| Capps Scott B |
VP, Clinical Research |
• – – |
2017-02-22 |
4 |
S |
$16.40 |
$181,776 |
D/D |
(11,083) |
117,394 |
|
- |
|
| Capps Scott B |
VP, Clinical Research |
• – – |
2017-02-22 |
4 |
OE |
$7.01 |
$116,836 |
D/D |
16,667 |
128,477 |
|
- |
|
| Mcdermid James M |
SVP, CHRO |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
6,280 |
9,676 |
|
- |
|
| Matthews William Robert |
Senior VP, Operations, Quality |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
6,280 |
36,300 |
|
- |
|
| Lee David Ashley |
Executive VP, COO & CFO |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,111 |
297,403 |
|
- |
|
| Mackin James P |
President & CEO |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
31,111 |
443,449 |
|
- |
|
| Holloway Jean F |
VP, General Counsel |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,536 |
52,153 |
|
- |
|
| Horton Amy |
VP, Chief Accounting Officer |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,111 |
96,117 |
|
- |
|
| Gale David C |
VP, Research & Development |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,778 |
80,887 |
|
- |
|
| Davis John E |
Senior VP, Global Sales |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,222 |
37,586 |
|
- |
|
| Capps Scott B |
VP, Clinical Research |
• – – |
2017-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,444 |
111,810 |
|
- |
|
| Matthews William Robert |
Senior VP, Operations, Quality |
• – – |
2017-02-19 |
4 |
D |
$17.25 |
$38,157 |
D/D |
(2,212) |
30,020 |
|
- |
|
| Matthews William Robert |
Senior VP, Operations, Quality |
• – – |
2017-02-19 |
4 |
A |
$17.25 |
$228,770 |
D/D |
13,262 |
32,232 |
|
- |
|
915 Records found
|
|
Page 28 of 37 |
|
|
0.50 (2.05%) 
